2023-10-25 07:32:38 ET
DENVER, Colo., Oct 25, 2023 ( www.247marketnews.com )- BioXcel Therapeutics Inc (NASDAQ: BTAI) reported, this morning, positive findings from an independent third-party audit of the data from a single site in its TRANQUILITY II Phase 3 trial. The independent audit was conducted by a consulting firm and consisted of a comprehensive review of records from over 50% of subjects enrolled at the single trial site to identify any additional instance of misconduct or fraud2 and to evaluate data integrity and reliability for eligibility, safety, and efficacy data. This sample size provides 95% confidence that the data reviewed is a representative sample. Following an extensive review, the team of auditors did not identify any findings that they believe impact the data …
The post BioXcel Therapeutics Reports Positive Independent Third-Party Findings from TRANQUILITY II Phase 3 Trial appeared first on 24/7 Market News .
For further details see:
BioXcel Therapeutics Reports Positive Independent Third-Party Findings from TRANQUILITY II Phase 3 Trial